A low profile Israeli biotech named Therapix Biosciences is taking a flier on a micro IPO on NASDAQ. The biotech has done some preclinical work on a combination of low dose dronabinol, an approved synthetic cannabinoid, with palmitoylethanolamide, or PEA, an endogenous fatty acid amide for treating Tourette syndrome. The biotech is looking to raise about $12 million, the latest in a series of micro IPOs that have been making the rounds recently as the IPO window has narrowed considerably over the course of the year. Here’s the F-1.
Seattle may not be the easiest place to find new recruits, says Juno co-founder Richard Klausner, but the CAR-T company isn’t going anywhere, for now. Klausner told GeekWire that New York Mayer Bill de Blasio personally tried to woo the company to New York, but the Juno board member says the West Coast city has a unique background in cell therapies that makes it a great home for Juno. Letting Amgen go ahead and close its research center in the city, though, was a mistake that Seattle will likely long lament.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription